Boda Weiye Clopidogrel Bisulfate Tablets Receive Drug Registration Certificate from the National Medical Products Administration

While being recognized by the Jilin Provincial Department of Science and Technology as a new-type R&D institution, Clopidogrel Hydrogen Sulfate Tablets, another member of the Boda Weiye family, proudly received the Drug Registration Certificate from the National Medical Products Administration on December 11.

Clopidogrel Hydrogen Sulfate Tablets

Chinese aliases: (S)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-methyl ester hydrogensulfate; clopidogrel hydrogensulfate; clopidogrel disulfate; clopidogrel sulfate; clopidogrel dipyrrolate Clopidogrel

Product Name: Ruivisheng

Manufacturing Company: Jilin Boda Weiye Pharmaceutical Co., Ltd.

Approval Number: National Medicine Approval Code H20203667

English Name: Clopidogrel Hydrogen Sulfate Tablets

Clopidogrel tablets are originally developed by Sanofi (trade name: Plavix), and are used to prevent and treat complications arising from myocardial infarction, ischemic cerebral thrombosis, obliterative arteritis, atherosclerosis, and thromboembolism. The medication is particularly indicated for patients who have recently experienced stroke, myocardial infarction, or have been diagnosed with peripheral arterial disease; after treatment, it can significantly reduce the occurrence of atherosclerotic events such as myocardial infarction, stroke, and vascular death. Globally, this product generates sales of US$10 billion, while its sales in China reach RMB 12 billion, making it a key product in the cardiovascular therapeutic drug market.

Beginning in January 2011, the chlorpyrifos active pharmaceutical ingredient underwent pilot-scale production at the Liaoyuan facility. After going through a series of rigorous processes—including technology transfer, on-site registration inspections, production site audits, process research, quality studies, stability assessments, and consistency evaluations—chlorpyrifos tablets, the result of countless efforts by the dedicated team at Weiye, have now successfully launched onto the market. It has brought good news to countless patients struggling with heart attacks, strokes, and peripheral arterial diseases.

Through wind and rain, we see the rainbow. Hold on, and you'll see the moon emerge from the clouds.

Clopidogrel has now been included in the National Essential Medicines List and the National Medical Insurance Catalogue. In the foreseeable future, after its market launch, annual sales revenue is expected to reach 300 million yuan, generating 100 million yuan in profits and taxes. Building on this success, under the framework of the 14th Five-Year Plan, Bodaweiyi's new product development and mass production will enter a period of rapid growth.